RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma

International Journal of Cancer

Volumn 132, Issue 9, 2013, Pages 2118-2126

  Tennstedt, Pierre ^a   Fresow, Robert ^a   Simon, Ronald ^a   Marx, Andreas ^a   Terracciano, Luigi ^b   Petersen, Cordula ^a   Sauter, Guido ^a   Dikomey, Ekkehard ^a   Borgmann, Kerstin ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

colorectal adenocarcinoma; DNA repair; EGFR; prognostic marker; RAD51

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MISMATCH REPAIR PROTEIN; MISMATCH REPAIR PROTEIN MLH; MISMATCH REPAIR PROTEIN MSH; PROTEIN P21; RAD51 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC MARKER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RAD51 GENE; SURVIVAL TIME; TISSUE MICROARRAY; UPREGULATION;

ADENOCARCINOMA; AGED; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RAD51 RECOMBINASE; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84874092959     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27907     Document Type: Article

References (49)

1. Walther A, Johnstone E, Swanton C, et al. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009; 9: 489-99.
2. Boland CR, Goel A,. Microsatellite instability in colorectal cancer. Gastroenterology 2010; 138: 2073-87.
3. Sinicrope FA, Sargent DJ,. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res 2012; 18: 1506-12.
4. Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011; 29: 1261-70.
5. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-74.
6. Javle M, Curtin NJ,. The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer 2011; 105: 1114-22.
7. Benson FE, Baumann P, West SC,. Synergistic actions of Rad51 and Rad52 in recombination and DNA repair. Nature 1998; 391: 401-4.
8. West SC,. Molecular views of recombination proteins and their control. Nat Rev Mol Cell Biol 2003; 4: 435-45.
9. Raderschall E, Stout K, Freier S, et al. Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res 2002; 62: 219-25.
10. Hansen LT, Lundin C, Spang-Thomsen M, et al. The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer. Int J Cancer 2003; 105: 472-9.
11. Slupianek A, Hoser G, Majsterek I, et al. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol 2002; 22: 4189-201.
12. Vispe S, Cazaux C, Lesca C, et al. Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res 1998; 26: 2859-64.
13. Maacke H, Jost K, Opitz S, et al. DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene 2000; 19: 2791-5.
14. Maacke H, Opitz S, Jost K, et al. Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int J Cancer 2000; 88: 907-13.
15. Qiao GB, Wu YL, Yang XN, et al. High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer 2005; 93: 137-43.
16. Connell PP, Jayathilaka K, Haraf DJ, et al. Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. Int J Oncol 2006; 28: 1113-19.
17. Soderlund K, Skoog L, Fornander T, et al. The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer. Radiother Oncol 2007; 84: 242-51.
18. Welsh JW, Ellsworth RK, Kumar R, et al. Rad51 protein expression and survival in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2009; 74: 1251-5.
19. Le Scodan R, Cizeron-Clairac G, Fourme E, et al. DNA repair gene expression and risk of locoregional relapse in breast cancer patients. Int J Radiat Oncol Biol Phys 2010; 78: 328-36.
20. Li Y, Yu H, Luo RZ, et al. Elevated expression of Rad51 is correlated with decreased survival in resectable esophageal squamous cell carcinoma. J Surg Oncol 2011; 104: 617-22.
21. Dasari A, Messersmith WA,. New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. Clin Cancer Res 2010; 16: 3811-18.
22. Dancau AM, Simon R, Mirlacher M, et al. Tissue microarrays. Methods Mol Biol 2010; 576: 49-60.
23. Marx AH, Burandt EC, Choschzick M, et al. Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Hum Pathol 2010; 41: 1577-85.
24. Lugli A, Zlobec I, Minoo P, et al. Prognostic significance of the wnt signalling pathway molecules APC, beta-catenin and E-cadherin in colorectal cancer: a tissue microarray-based analysis. Histopathology 2007; 50: 453-64.
25. Engstrom PF, Arnoletti JP, Benson AB, III, et al.; National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw 2009; 7: 778-831.
26. Helleday T, Lo J, van Gent DC, et al. DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst) 2007; 6: 923-35.
27. Asakawa H, Koizumi H, Koike A, et al. Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins. Breast Cancer Res 2010; 12: R17.
28. Richardson C, Stark JM, Ommundsen M, et al. Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability. Oncogene 2004; 23: 546-53.
29. Francis R, Richardson C,. Multipotent hematopoietic cells susceptible to alternative double-strand break repair pathways that promote genome rearrangements. Genes Dev 2007; 21: 1064-74.
30. Shammas MA, Shmookler Reis RJ, Koley H, et al. Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. Blood 2009; 113: 2290-7.
31. Pal J, Bertheau R, Buon L, et al. Genomic evolution in Barrett's adenocarcinoma cells: critical roles of elevated hsRAD51, homologous recombination and Alu sequences in the genome. Oncogene 2011; 30: 3585-98.
32. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
33. Tsuzuki T, Fujii Y, Sakumi K, et al. Targeted disruption of the Rad51 gene leads to lethality in embryonic mice. Proc Natl Acad Sci USA 1996; 93: 6236-40.
34. Mohrin M, Bourke E, Alexander D, et al. Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell 2010; 7: 174-85.
35. Ross JS, Torres-Mora J, Wagle N, et al. Biomarker-based prediction of response to therapy for colorectal cancer: current perspective. Am J Clin Pathol 2010; 134: 478-90.
36. Gupta S, Ashfaq R, Kapur P, et al. Microsatellite instability among individuals of Hispanic origin with colorectal cancer. Cancer 2010; 116: 4965-72.
37. Yan T, Seo Y, Kinsella TJ,. Differential cellular responses to prolonged LDR-IR in MLH1-proficient and MLH1-deficient colorectal cancer HCT116 cells. Clin Cancer Res 2009; 15: 6912-20.
38. Rajesh P, Rajesh C, Wyatt MD, et al. RAD51D protects against MLH1-dependent cytotoxic responses to O(6)-methylguanine. DNA Repair (Amst) 2010; 9: 458-67.
39. Wyatt MD, Wilson DM, III,. Participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci 2009; 66: 788-99.
40. Giralt J, de las Heras M, Cerezo L, et al.; Grupo Español de Investigacion Clinica en Oncologia Radioterápica (GICOR). The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiother Oncol 2005; 74: 101-8.
41. Kasten-Pisula U, Saker J, Eicheler W, et al. Cellular and tumor radiosensitivity is correlated to epidermal growth factor receptor protein expression level in tumors without EGFR amplification. Int J Radiat Oncol Biol Phys 2011; 80: 1181-8.
42. Chinnaiyan P, Huang S, Vallabhaneni G, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005; 65: 3328-35.
43. Ko JC, Ciou SC, Jhan JY, et al. Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells. Mol Cancer Res 2009; 7: 1378-89.
44. Chen RS, Jhan JY, Su YJ, et al. Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation. Exp Cell Res 2009; 315: 2658-72.
45. Golding SE, Morgan RN, Adams BR, et al. Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. Cancer Biol Ther 2009; 8: 730-8.
46. Zhang S, Yu D,. PI(3)king apart PTEN's role in cancer. Clin Cancer Res 2010; 16: 4325-30.
47. Koch K, Wrona A, Dikomey E, et al. Impact of homologous recombination on individual cellular radiosensitivity. Radiother Oncol 2009; 90: 265-72.
48. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66: 8109-15.
49. Morgan MA, Parsels LA, Zhao L, et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 2010; 70: 4972-81.